by: Parent Project Muscular Dystrophy
Edgewise Therapeutics has announced the initiation of the ARCH open label study of EDG-5506 in Becker muscular dystrophy, which will enroll participants from its Phase 1b clinical trial as well as new participants with Becker. We are also pleased to learn that Edgewise will report topline results from the Phase 1b clinical trial of EDG-5506 on January 5th, with hopes to initiate a Phase 2 study in Becker in the first half of 2022 and a Phase 2 study in Duchenne in the last half of 2022.
About EDG-5506
EDG-5506 is an oral small molecule muscle stabilizer which seeks to protect the muscle from injuries when dystrophin is absent or reduced. By helping to shield the muscle from damage and limit the muscle breakdown EDG-5506 may provide benefit to individuals living with Duchenne and Becker regardless of mutation.
